[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-traumatic-stress-disorder-ptsd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-traumatic-stress-disorder-ptsd":246},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,45,76,110,138,162,187,210,234,253,278,312,336,348,374,399,434,465,487,507,531,561,586,624,648],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053895","tms-for-ptsd-in-youth-100053895",false,"NCT07401225","TMS for PTSD in Youth","Transcranial Magnetic Stimulation as Treatment for Persistent PTSD in Texas Youth","Inclusion Criteria:\n\n1. Males and females; Age 12-20\n2. Have previously completed at least 9 sessions of trauma-focused therapy in our clinical trial or in the community\n3. Have current self-reported symptom score of 20 or greater on the UCLA PTSD Reaction index\n4. Willing to attend 10 TMS treatment sessions within a 30-day period\n5. Fluent in English\n\nExclusion Criteria:\n\n1. History of seizures\n2. History of head injury with loss of consciousness and concussive sequelae\n3. Brain abnormality such as tumor or other observable abnormality\n4. Currently receiving psychotherapy or TMS treatment\n5. Currently pregnant\n6. MRI contraindications (metal in body, orthodontic braces)\n7. Diagnosis of bipolar 1 or a psychotic disorder","ALL","12 Years","20 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to test whether transcranial magnetic stimulation, or TMS, is an acceptable and helpful treatment for ongoing symptoms of posttraumatic stress syndrome disorder (PTSD) in 12-20 year olds. Ongoing PTSD refers to symptoms that continue after completing trauma-focused psychotherapy. About 1 in 4 patients need additional help to overcome PTSD after completing psychotherapy. Currently, scientists do not know the best way to help adolescents with persistent PTSD, and this study will test TMS as a possible treatment, and hopefully lead to future studies including more people.",[28],"Post Traumatic Stress Disorder (PTSD)",[30,31],"Transcranial Magnetic Stimulation","Transcranial Magnetic Stimulation (TMS)","RECRUITING","2026-07-09",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2026-05-09",{"date":40,"type":22},"2027-08-31",{"name":42,"class":43},"The University of Texas Health Science Center at San Antonio","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100528589","type-i-hybrid-effectiveness-implementation-trial-of-primary-care-brief-mindfulness-training-for-veterans-100528589","NCT06162741","Type I Hybrid Effectiveness-Implementation Trial of Primary Care Brief Mindfulness Training for Veterans","Inclusion Criteria:\n\nTo be eligible, participants must be:\n\n* enrolled in VA primary care through the local VA site\n* report clinically significant psychological distress as measured in at least one of three areas:\n\n  * PTSD operationalized by 30 on the PCL-5 plus endorsing a criteria A stressor\n  * depression operationalized as 10 on the PHQ-9\n  * anxiety operationalized by 10 on the GAD-7\n\nExclusion Criteria:\n\nExclusion criteria are minimized to allow inclusion of any primary care patients with psychological distress that would normally receive treatment in primary care. Patients will be excluded if they demonstrate symptoms that would not allow them to actively participate in the interventions:\n\n* gross cognitive impairment\n* suicide attempt or desire to commit suicide in the last month\n\nTo allow the study to isolate the effects of the intervention and ensure patient treatment preferences are honored, patients will be excluded if they:\n\n* had a psychotherapy appointment outside of primary care within the last month and have future appointment scheduled\n* had a change in psychiatric medication outside of VHA primary care in the last 2 months\n* voice a preference to be directly referred to specialty mental health care\n\nVeterans with mild TBI, and alcohol\u002F substance use disorders will not be excluded because these problems commonly co-occur with psychological distress, and individuals with these conditions have previously benefited from mindfulness and problem-solving training. Patients who receive Primary Care Mental Health Integration (PCMHI) services will not be excluded as this is part of the usual primary care services that all Veterans receive.","18 Years",{"count":53,"type":22},300,[25],"The VA wants to understand what type of integrative and whole health approaches are helpful for Veterans. The study is comparing two primary care based mental health treatments, a mindfulness class that teaches mindfulness meditation and a problem-solving class that teaches problem-solving skills and how to build resilience, for Veterans who are experiencing symptoms of anxiety, depression, and\u002For PTSD. The goal of the study is to understand if the classes reduce symptoms of anxiety, depression, and\u002For PTSD and increase overall functioning.",[28,57,58],"Depression","Anxiety",[60,28,61,62,63,57,58,64],"Psychological Distress","Mindfulness","Primary Care","Brief Intervention","Problem-solving training","2026-06-30",{"date":67,"type":36},"2026-07-02",{"date":69,"type":36},"2024-08-19",{"date":71,"type":22},"2027-12-31",{"name":73,"class":74},"VA Office of Research and Development","FED",4,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":44},"100645324","accelerated-itbs-for-ptsd-and-depression-100645324","NCT07682207","Accelerated iTBS for PTSD and Depression","Accelerated Intermittent Theta Burst Stimulation for Depression in Post-Traumatic Stress Disorder: A Single-Arm, Open-Label Feasibility Study","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Current post-traumatic stress disorder (PTSD) and current major depressive disorder (MDD), confirmed by a structured diagnostic interview (e.g., MINI 6.0 using the PTSD and MDD modules).\n* Minimum symptom severity at baseline: HAMD-17 score ≥14 (moderate depression) and\u002For PCL-5 score ≥33 (probable PTSD).\n* On a stable pharmacologic and\u002For psychotherapeutic regimen for at least 4 weeks prior to baseline, and willing to maintain stability during the treatment phase, unless medically necessary.\n* Capacity to provide informed consent and comply with study procedures and visits at St. Joseph's Health Care, London\u002FParkwood Institute.\n* Sufficient English proficiency to complete consent and study assessments.\n\nExclusion Criteria:\n\n* Neurologic or device-related risks, including seizure history, traumatic brain injury with loss of consciousness greater than 5 minutes, major neurologic illness, or metal\u002Felectronic implants contraindicated for transcranial magnetic stimulation.\n* Psychiatric or substance-related risks, including current psychotic disorder, acute mania, diagnosis of Bipolar I or Bipolar II disorder, recent substance use disorder, or imminent suicide risk.\n* Medical or medication-related risks, including unstable severe illness, high-risk medications, hearing impairment, unwillingness to use ear protection, or prior non-response to an adequate course of theta burst stimulation for the current depression\u002FPTSD episode.\n* Enrollment in another interventional trial.\n* Inability to comply with the study schedule.",{"count":84,"type":22},16,[25],"The goal of this pilot clinical trial is to learn if a faster brain stimulation schedule is practical, safe, tolerable, and acceptable. This study looks at accelerated intermittent theta burst stimulation, or accelerated iTBS. This is a non-invasive type of magnetic brain stimulation. This study is for adults with post-traumatic stress disorder (PTSD) and major depressive disorder (MDD).\n\nThe main questions this study aims to answer are:\n\n1. Can participants complete six short brain stimulation sessions per day for five days?\n2. Is this treatment schedule safe and tolerable for participants?\n3. What changes occur in depression symptoms, PTSD symptoms, anxiety, quality of life, and brain activity over time?\n\nParticipants will:\n\n1. Complete health screening and baseline assessments.\n2. Receive six short sessions of magnetic brain stimulation per day for five days.\n3. Have their brain activity measured using an EEG recording.\n4. Return for a post-treatment assessment at Week 2 and follow-up visits at Week 5 and Week 12.",[88,89],"Post Traumatic Stress Disorder PTSD","Major Depressive Disorder (MDD)",[91,92,57,93,94,95,96,97,98,99,100],"PTSD","MDD","Feasibility study","Accelerated intermittent theta burst stimulation","iTBS","Theta burst stimulation","Transcranial magnetic stimulation","TMS","Brain stimulation","EEG","NOT_YET_RECRUITING","2026-06-26",{"date":67,"type":36},{"date":105,"type":22},"2026-07",{"date":107,"type":22},"2027-09",{"name":109,"class":43},"Lawson Research Institute of St. Joseph's",{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":117,"minAge":51,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":137},"100644226","pre-pilot-wings-mhealth-to-improve-moud-uptake-in-women-experiencing-intimate-partner-violence-and-ptsd-100644226","NCT07665502","Pre-Pilot WINGS+++: mHealth to Improve MOUD Uptake in Women Experiencing Intimate Partner Violence and PTSD","Pre-Pilot WINGS +++ An Effectiveness Trial of Syndemic Mhealth Intervention to Increase MOUD Uptake Among Women Impacted by Intimate Partner Violence and PTSD","Inclusion Criteria:\n\n* Identify as a woman (cis-gender or transgender)\n* Aged 18 or older\n* Report use of non-prescribed opioids in the past 30 days\n* Score positive for risk of opioid use disorder or other substance use disorder on the Drug Abuse Screening Test (DAST) with a cut-off score of 6 or higher\n* Report experiencing any severe psychological abuse or any physical or sexual abuse by a female or male intimate partner in the past year\n\nExclusion Criteria:\n\n* Evidence of significant psychiatric or cognitive impairment that would limit effective participation, as confirmed during informed consent\n* Inability to speak and understand English sufficiently to participate in assessments or intervention sessions","FEMALE",{"count":119,"type":22},7,[25],"The goal of this pre-pilot for the clinical trial is to develop a mobile health (mHealth) program called WINGS+++ can help women with opioid use disorder or other substance use disorders who have experienced intimate partner violence. The pre-pilot study will take place in Orange County, New York with n=7 women. .\n\nThe main questions it aims to answer are:\n\n1. Does WINGS+++ lower non-prescription opioid and other drug use in women?\n2. Does WINGS+++ help connect women to treatment for substance use, intimate partner violence, and post-traumatic stress disorder (PTSD)?\n\nResearchers will compare WINGS+++ to standard care to see if WINGS+++ works better to lower drug use and link women to helpful services.\n\nWINGS+++ is a 3-session program on a mobile device that:\n\n* Screens for intimate partner violence, PTSD, and substance use\n* Offers brief support and referrals based on each woman's needs and preferences\n* Connects women to a peer navigator who helps link them to services\n\nParticipants will:\n\n* Take part in only the WINGS+++ program for the pre-pilot\n* Answer survey questions about drug use, intimate partner violence, and PTSD symptoms\n* Provide biological samples (such as urine or hair) to check for drug use\n* Share information about the services they have used",[123,124,125,126,127,128,88],"Opioid-Related Disorders","Substance-Related Disorders","Intimate Partner Violence (IPV)","Stress Disorders, Post-Traumatic","Domestic Violence","Medication for Opioid Use Disorder (MOUD)","2026-06-18",{"date":131,"type":36},"2026-06-24",{"date":133,"type":22},"2026-06-15",{"date":40,"type":22},{"name":136,"class":43},"Dawn A. Goddard-Eckrich",2,{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":159,"leadSponsor":161,"locationsCount":137},"100643969","the-effects-of-stellate-ganglion-block-sleep-in-us-active-duty-service-members-and-veterans-receiving-prolonged-exposure-therapy-for-ptsd-100643969","NCT07667309","The Effects of Stellate Ganglion Block Sleep in U.S. Active Duty Service Members and Veterans Receiving Prolonged Exposure Therapy for PTSD","The Effects of Stellate Ganglion Block on Sleep in U.S. Active Duty Service Members and Veterans Receiving Prolonged Exposure Therapy for Posttraumatic Stress Disorder (PTSD)","Inclusion Criteria:\n\n1. Ability to provide informed consent and follow study-related instructions.\n2. Be randomized into the study titled \"Combining Stellate Ganglion Block with Prolonged Exposure for PTSD: A Randomized Clinical Trial.\" NCT05889741\n3. Indicates willingness to wear the Sleep Profiler sleep monitor and to complete self-report assessments.\n\nExclusion Criteria:\n\n1\\. Pre-existing skin or soft tissue condition that precludes the ability to wear the Sleep Profiler headband.","65 Years",{"count":147,"type":22},40,"OBSERVATIONAL","Participants in this study will have already been enrolled in another research study: Combining Stellate Ganglion Block with Prolonged Exposure for PTSD, NCT05889741. The investigators are using a Sleep Profiler, EEG headband to monitor a participants brainwaves while they sleep to see what effects the Stellate Ganglion Block injection has on their sleep. Participants will wear the headband for 3 nights before the injection and then 3 nights after the injection. Participants will also complete self-report questionnaires regarding their sleep prior to the injection and following the injection. Approximately 40 participants will be included in this study. This study is a nested observational study whereby participants in the parent study who elect to participate will have their sleep assessed using the EEG headband device and self-reported sleep measures performed.",[88],[152,153,91,154,155],"Stellate Ganglion Block","Sleep Profiler","Sleep","Sleep architecture",{"date":157,"type":36},"2026-06-25",{"date":133,"type":22},{"date":160,"type":22},"2027-06-30",{"name":42,"class":43},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":17,"minAge":170,"maxAge":145,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":137},"100568272","phase-2-suvorexant-for-treatment-of-aud-and-ptsd-100568272","NCT06679062","Suvorexant for Treatment of AUD and PTSD","A Double-masked, Randomized, Phase II Study to Compare the Effectiveness of 20mg Oral Suvorexant (SUV) Versus Placebo (1:1) in Participants With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)","SUV","Inclusion Criteria:\n\n* Age between 21 and 65.\n* Meet current (i.e., past 12-month at Day -7\u002F-6) DSM-5 diagnostic criteria for moderate or severe AUD as determined by the MINI.\n* Currently experiencing PTSD symptoms at screening (Day -7\u002F-6) as indicated by PCL-5 cut-score \\> 30.\n* Intrinsic motivation to reduce or quit drinking (defined as self-reported intention at screening to reduce or quit drinking within the next 6 months) and to receive PTSD treatment.\n* Must have an ISI score equal to or \\> 7 (subthreshold insomnia). ISI score below 7 at screening will not be included or proceed beyond the screening day.\n* Agree to abstain from all other sleep medications (starting at Day -7).\n* Have a place to live in the 2 weeks prior to randomization (Day 0) and not be at risk that s\u002Fhe will lose his\u002Fher housing in the next month.\n\nExclusion Criteria:\n\n* A current (past 12-month at Day -7\u002F-6) DSM-5 diagnosis via the MINI of substance use disorder for any substances other than alcohol, nicotine, or marijuana (\\\u003C moderate level on DSM 5).\n* A lifetime DSM-5 diagnosis via the MINI of schizophrenia, bipolar disorder, or psychotic disorder.\n* Positive urine test for any recreational drugs other than marijuana at screening (Day -7\u002F-6).\n* Current clinically significant alcohol withdrawal (i.e., score ≥ 10 on the CIWA-Ar).\n* Currently pregnant, nursing, or no reliable method of birth control (females only).\n* Any clinically significant medical condition that would preclude safe participation in the study (e.g. narcolepsy, seizure disorder, or other clinically significant cardiovascular, hematologic, hepatic, renal, neurological, or endocrine disorders).\n* Use of suvorexant (within 30 days of Day -7).\n* Currently on prescription medication that contraindicates use of suvorexant (including moderate or strong Cytochrome P450 3A modulators (CYP3A inhibitors and inducers))\n* Hepatic insufficiency (AST\u002FALT \\> 5x upper limit of normal (ULN)).\n* Suicidal Ideation determined by greater than moderate Columbia Suicide Severity Rating Scale.\n* Inability to provide evidence of 48-hour alcohol abstinence (self-report, BrAC, EtG) at Day 0 AND failure after second attempt at 48-hour abstinence.","21 Years",{"count":172,"type":22},76,[174],"PHASE2","This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol use disorder (AUD). All participants will have a 7-day placebo run-in period, followed by a random assignment to receive placebo or suvorexant for an additonal 14 days. Post-randomization, participants will attempt to stop drinking for two weeks and will complete daily virtual diaries and study outcome assessments via in-person clinic visits on days 7 and 14.",[177,28,178],"Alcohol Use Disorder (AUD)","Insomnia",{"date":180,"type":36},"2026-06-23",{"date":182,"type":36},"2025-07-16",{"date":184,"type":22},"2027-03",{"name":186,"class":43},"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":194,"sex":17,"minAge":51,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":44},"100630526","imaging-phosphodiesterase-4b-pde4b-in-people-with-psychiatric-disorders-with-positron-emission-tomography-pet-and-the-radiotracer-18fpf974-100630526","NCT07488819","Imaging Phosphodiesterase 4B (PDE4B) in People With Psychiatric Disorders With Positron Emission Tomography (PET) and the Radiotracer [18F]PF974","Imaging PDE4B in People With Psychiatric Disorders With PET and the Radiotracer [18F]PF974","Inclusion Criteria:\n\n1. Willing and able to give voluntary written informed consent.\n2. Is able to read and write, able to communicate effectively with the investigator, and comply with all study requirements, restrictions, and directions of the research staff.\n3. Men or women, aged 18 to 70, at screening.\n4. In good general health as evidenced by medical history, physical examination, electrocardiogram, serum\u002Furine biochemistry, hematology, and serology tests.\n5. Participants with AUD will have a current diagnosis of AUD according to DSM-5 criteria (i.e., Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) (SCID-5) ascertained diagnosis, confirmed by the Principal Investigators).\n6. Participants with AUD will meet the following drinking criteria: males will drink \\> 14 drinks per week and exceed 4 drinks per day at least twice per week; females will drink \\> 7 drinks per week and exceed 3 drinks per day at least twice per week. They must meet drinking criteria during a consecutive 30-day period within the 90 days prior to intake.\n7. Participants with PTSD will have a current diagnosis of PTSD according to DSM-5 criteria (CAPS-5 ascertained diagnosis, confirmed by the Principal Investigators. TC subjects must have a DSM-5 criteria traumatic event with no PTSD diagnosis.\n8. Healthy control subjects will have no current or past diagnosis of AUD or other significant substance use disorder. They will drink less than 5 alcoholic drinks per week with no heavy drinking days (i.e., \\>4 drinks\u002Fday for men; \\>3 drinks\u002Fday for women) in the last 30 days. Subjects who have have a DSM-5 criteria traumatic event with no PTSD diagnosis may also be considered healthy controls for Aim 1.\n9. Renal function and hepatic function will be within normal limits (for age and sex) on the laboratory tests. Elevated liver enzymes for individuals with alcohol use disorder are permitted at the discretion of the study physician.\n\nExclusion Criteria:\n\n1. Current significant medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology that would impact the integrity of the data (note that elevated liver enzymes for individuals with AUD will not be exclusionary).\n2. Past or current neurological disorder or disorders affecting the brain including but not limited to multiple sclerosis, history of stroke, brain tumors, traumatic brain injury with loss of consciousness, seizure disorder.\n3. Current significant psychiatric disorder including severe substance use disorder (other than alcohol or tobacco use disorders\\*) and past or current psychotic symptoms.\n4. Regular use in the past 6 months of any prescription, psychoactive or herbal medications (e.g., antidepressants, antipsychotics, anxiolytics) that would impact the integrity of the data; No subject will be asked to stop taking medication to participate in the study. Participants who are regularly taking P-gp and BCRP inhibitors will be excluded.\n5. Pregnancy or lactation.\n6. Blood donation within eight weeks of the start of the study.\n7. History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto).\n8. Unable to safely discontinue or hold aspirin and other NSAID use.\n9. MRI incompatible implants (i.e., such as pacemaker, artificial joints, non-removable body piercings) and other contraindications for MRI, such as claustrophobia, having implanted or embedded metal objects\u002Ffragments or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or machinist).\n10. Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits for healthy volunteers.\n11. Subject who has current, past, or anticipated exposure to radiation in the work place within one year of the proposed research scans that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits.\n12. Has any condition that, in the opinion of the investigator, would prevent compliance with the study protocol.\n13. History of complicated alcohol withdrawal including history of delirium tremens; seizure, hospitalization for withdrawal.\n14. A CIWA score ≥8 at intake or on scan day.\n15. Subjects who are, in the opinion of the study physician, unable to safely abstain from alcohol overnight prior to their study visits.\n16. Subjects with a significant history of repeated alcohol withdrawal, defined as 4 or more medicated detoxifications in the previous 5 years",true,"70 Years",{"count":197,"type":22},160,"Imaging PDE4B in people with psychiatric disorders with PET and the radiotracer \\[18F\\]PF974",[200,177],"Post-Traumatic Stress Disorder, PTSD","2026-06-10",{"date":203,"type":36},"2026-06-11",{"date":205,"type":36},"2025-07-07",{"date":207,"type":22},"2032-03-01",{"name":209,"class":43},"Yale University",{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":145,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":44},"100510705","open-trial-of-trauma-focused-psychodynamic-psychotherapy-for-people-living-with-hiv-and-ptsd-100510705","NCT05929911","Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD","Pilot Feasibility Proposal to Adapt Trauma-focused Psychodynamic Psychotherapy (TFPP) for PLWH and PTSD","TFPP-PLWH","Inclusion Criteria:\n\n* Diagnosis of DSM-5 defined PTSD, per the Clinician Administered PTSD Scale \\& CAPS-5 total severity score greater than or equal to 25\n* HIV diagnosis (by medical records or HIV testing)\n* Stable psychiatric\u002Fpsychotropic medication for \\>=2 months and ongoing during treatment\n\nExclusion Criteria:\n\n* Psychosis\n* Bipolar I\n* Acute suicidality\n* Current substance use disorder\n* Organic mental syndrome or intellectual disability\n* Unstable non-HIV medical conditions",{"count":21,"type":22},[25],"People living with HIV (PLWH) have a higher rate of post-traumatic stress disorder (PTSD) diagnosis than the general population. Comorbid PTSD is also associated with negative HIV-related health outcomes. Unfortunately, little outcome research has examined the usefulness of PTSD treatments for PTSD. This pilot study adapts for PLWH a non-exposure based psychotherapy for PTSD focused on reflecting on one's emotions and relationships and understanding and working through how trauma may have disrupted them. The study team is interested in better understanding the needs of PLWH with PTSD, learning whether PLWH with PTSD find this treatment acceptable and helpful, and beginning to understand the relationship between HIV-related health factors (e.g., inflammation and stress biology) and PTSD, and how these health factors may improve during treatment.",[28,222],"HIV",[222,224,225],"psychotherapy","trauma",{"date":227,"type":36},"2026-06-12",{"date":229,"type":36},"2024-04-26",{"date":231,"type":22},"2027-06",{"name":233,"class":43},"Montefiore Medical Center",{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":250,"leadSponsor":251,"locationsCount":44},"100643368","the-efficacy-and-safety-of-temporal-interference-stimulation-in-the-treatment-of-post-traumatic-stress-disorder-100643368","NCT07644338","The Efficacy and Safety of Temporal Interference Stimulation in the Treatment of Post-Traumatic Stress Disorder","Inclusion Criteria:\n\n1. Age 18-50 years, male or female\n2. Diagnosis of PTSD per DSM-5 (assessed by CAPS-5), with symptom duration of at least 3 months, and PTSD as the current primary diagnosis; comorbid depressive disorder or anxiety disorder is allowed\n3. If currently receiving psychiatric medication, the dosage must be stable for at least 4 weeks prior to enrollment\n4. At least 9 years of education (junior high school or above)\n\nExclusion Criteria:\n\n1. Any DSM-5 diagnosis other than PTSD, depressive disorder, or anxiety disorder\n2. PTSD symptoms too severe to complete required assessments\n3. Received electroconvulsive therapy (ECT) within the past 6 months\n4. Received any other form of neuromodulation within the past 2 months (see Item 3 for ECT)\n5. Severe medical illness or any condition that may induce seizures or intracranial hypertension (e.g., cardiovascular or respiratory diseases)\n6. History of neurological disorders (e.g., epilepsy, cerebrovascular accident) or brain injury\u002Fsurgery\n7. Presence of intracranial stents, cardiac pacemakers, coronary stents, cochlear implants, or any other MRI-incompatible implants\n8. Current significant suicidal behavior risk per investigator judgment\n9. Pregnancy or planning to become pregnant during the study period\n10. Initiation of structured psychotherapy for PTSD within 3 months prior to screening, with expected change during the 10-week treatment period","50 Years",{"count":242,"type":22},5,[25],"This study aims to evaluate the efficacy and safety of Temporal Interference (TI) stimulation in treating patients with post-traumatic stress disorder (PTSD) and to explore its potential neural mechanisms using magnetic resonance imaging (MRI) ,magnetoencephalography（MEG）,electroencephalography (EEG).",[246],"Post-traumatic Stress Disorder (PTSD)","2026-06-08",{"date":227,"type":36},{"date":247,"type":36},{"date":231,"type":22},{"name":252,"class":43},"Shanghai Mental Health Center",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":117,"minAge":51,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":274,"leadSponsor":276,"locationsCount":277},"100601787","project-stronger-stepped-care-for-opioid-use-disorder-treatment-engagement-and-recovery-100601787","NCT07115030","Project STRONGER: Stepped Care for Opioid Use Disorder Treatment Engagement and Recovery","STRONGER","Inclusion Criteria:\n\n* Woman;\n* Are ≥ 18 years old;\n* Receive MOUD treatment at one of the participating sites;\n* Have received MOUD for \\>14 days to allow for initial stabilization;\n* Have initiated the current treatment episode within the past 12 months;\n* Experienced physical or psychological IPV in their lifetime;\n* Have at least moderate impairment in psychosocial functioning (on B-IPF) as a result of PTSD symptoms;\n* Available during the date\u002Ftime of the intervention group\n* Able to read\u002Funderstand English; and\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* Fail a capacity-to-consent questionnaire;\n* Have an unstable medical condition (e.g., hospitalization, planned surgery, newly starting chemotherapy, plans for palliative care) and\u002For unstable psychiatric illness (e.g., untreated psychosis) that would interfere with their ability to participate in study activities;\n* Will be unavailable for \\>4 consecutive weeks during the study period (e.g., anticipated move, planned surgery);\n* Are unable to read\u002Funderstand English;\n* Inability to provide at least one form of contact",{"count":261,"type":22},532,[25],"Using a hybrid type 1 effectiveness-implementation approach, this study aims to evaluate the impact of a novel stepped care model (\"PCT+2HOPE\") versus treatment as usual (TAU) on increasing retention in community-based medication for opioid use disorder (MOUD) treatment among women who have experienced intimate partner violence (W-IPV). PCT+2HOPE includes Present-Centered Therapy (PCT+) with stepped care as indicated by moderate, severe, or extreme PTSD-related impairment in psychosocial functioning to Helping to Overcome PTSD through Empowerment (HOPE), two evidence-based behavioral interventions adapted for women with opioid use disorder (OUD). We will examine the effectiveness of PCT+2HOPE vs. TAU on the primary outcome (i.e., retention in MOUD treatment) and secondary outcomes related to trauma (i.e., PTSD-related impairment in psychosocial functioning and depression), substance use (i.e. OUD symptom severity, extra-medical opioid use \\[i.e., use of prescription opioids without a doctor's prescription; in greater amounts, more often, longer than prescribed, or for a reason other than a doctor said they should be used\\], and recovery), and empowerment. We will explore the extent to which the effectiveness of PCT+2HOPE vs. treatment as usual differs based on access to basic needs. We will also conduct an implementation-focused process evaluation.",[265,125,88],"Opioid Use Disorder",[267,268,269],"opioid use disorder","intimate partner violence","domestic violence","2026-06-01",{"date":272,"type":36},"2026-06-03",{"date":270,"type":36},{"date":275,"type":22},"2029-08-31",{"name":209,"class":43},3,{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":288,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":44},"100616722","psychosocial-factors-and-efficacy-of-remote-cognitive-remediation-for-post-traumatic-stress-disorder-100616722","NCT07309302","Psychosocial Factors and Efficacy of Remote Cognitive Remediation for Post-Traumatic Stress Disorder","Psychosocial Determinants and Impact of a Synchronous Remote Cognitive Remediation Program on Individuals With Post-Traumatic Stress Disorder.","Inclusion Criteria\n\n* Age 18 to 45 years\n* Able to speak and read French fluently\n* Access to a computer with a camera and a secure Internet connection\n* Access to a private space for assessment and intervention sessions\n* Available for the complete treatment protocol\n* Confirmed current PTSD diagnosis using the Structured Clinical Interview for DSM-5 (SCID-5)\n* Residing in Canada\n\nExclusion Criteria\n\n* History of neurological disorders (stroke, intracranial surgery, aneurysm, epilepsy)\n* Moderate to severe traumatic brain injury OR hospitalization due to traumatic brain injury\n* Mild traumatic brain injury less than 6 months ago with persistent symptoms\n* Psychotic disorders\n* Alcohol abuse or substance dependence disorders\n* Video game addiction\n* Hospitalization for major depression or suicide risk within the past 3 months\n* Regular use of medications that impact neurocognition, including: benzodiazepines (diazepam, lorazepam, alprazolam, Ativan, Xanax, Rivotril)\n* Residence outside Canada","45 Years",{"count":287,"type":22},64,[25],"The goal of this clinical trial is to evaluate whether computer-based brain training can help adults with post-traumatic stress disorder (PTSD). Individuals with PTSD often experience difficulties with memory, attention, concentration, and problem-solving, which can significantly affect their daily lives, work performance, and overall quality of life. These cognitive challenges can hinder trauma recovery and reduce the effectiveness of standard PTSD treatments.\n\nThe main questions this study seeks to address are:\n\nDoes specialized brain training improve PTSD symptoms compared to regular computer games? Does brain training enhance cognitive functions such as memory, attention, processing speed, and executive functioning? Does brain training improve quality of life and daily functioning? Do participants' self-efficacy and perceived social support influence treatment outcomes?\n\nResearchers will compare two approaches: a specialized cognitive training program (HAPPYneuron Pro) with strategy teachings and quality-of-life discussions, versus engaging computer games with quality-of-life discussions, to determine which is more effective for people with PTSD.\n\nStudy Design\n\nParticipants will be randomly assigned to one of two groups for an 8-week program:\n\nCognitive remediation training group: Complete computerized cognitive exercises and strategy teachings specifically designed to strengthen memory, attention, and executive functions, combined with quality-of-life discussions.\n\nControl group: Complete engaging computer games combined with quality-of-life discussions.\n\nSchedule\n\nBoth groups will follow the same schedule:\n\nOne online session per week, in small and consistent groups of 4-8 participants. Each 60-minute session consists of 30 minutes of computer activities followed by 45 minutes of group discussion.\n\nOne at-home individual homework exercise per week (30 minutes at home).\n\nTotal time commitment: 1h45 per week for 8 weeks.\n\nAssessments All participants will complete three comprehensive assessment sessions: before treatment, immediately after the 8-week program, and 3 months later. Assessments include neuropsychological testing and questionnaires on PTSD symptoms, depression, anxiety, quality of life, satisfaction with life, social support, cognitive failures, and self-efficacy.\n\nSignificance This research evaluates a new, accessible and remotely deliverable approach for PTSD treatment. Current evidence-based treatments often do not directly target the cognitive impairments experienced by many individuals with PTSD.\n\nCompensation Participants will receive $35 for each completed assessment (maximum $105). Control group participants will gain access to the cognitive remediation training program after completing their participation.",[88],[292,293,294,295,296,57,58,297,298,299,300,301,302],"Cognitive remediation","Social Support","Quality of Life","Online Intervention","Self-Efficacy","Attention","Verbal Memory","Executive Functions","Life Satisfaction","Post-Traumatic Stress Disorder","Neuropsychological functions","2026-05-13",{"date":305,"type":36},"2026-05-18",{"date":307,"type":36},"2025-08-03",{"date":309,"type":22},"2026-12",{"name":311,"class":43},"Université du Québec a Montréal",{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":145,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":320,"briefSummary":321,"conditions":322,"keywords":323,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":137},"100584181","phase-2-psilocybin-assisted-therapy-for-post-traumatic-stress-disorder-in-survivors-of-intimate-partner-violence-100584181","NCT06885996","Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence","PsiPTSD","Inclusion Criteria:\n\n* Individuals of all sexes, gender identities, and ethnicities\n* Ages 19 to 65 years at the time of screening\n* At least 6 months since last IPV incident\n* A score of 1 on the Composite Abuse Scale with repetition of abusive events\n* Minimum PCL-5 score of ≥ 33\n* Limited lifetime use of serotonergic hallucinogens\n* Ability to read\u002Fwrite English\n\nExclusion Criteria:\n\n* Severe or moderate substance use disorder other than nicotine in past 6 months\n* Lifetime diagnosis of schizophrenia or bipolar disorders (or first or second-degree relative)\n* Active suicidal ideation or serious attempt within the past 1 year.\n* Current pregnancy or nursing, trying to become pregnant\n* Any notable abnormality on ECG or routine medical blood laboratory test\n* Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia\n* Epilepsy with a history of seizures\n* Current or recent (within 12 weeks) participation in a clinical trial\n* Cognitive impairment (SLUMS score \\\u003C20)\n* Suffered a moderate\u002Fsevere TBI at least once in lifetime\n* Suffered a mild TBI within the last 6 months\n* Any other circumstances that, in the opinion of the investigators, compromises participant safety\n* Not compelled to enter treatment to avoid legal consequences",{"count":172,"type":22},[174],"The goal of this randomized controlled trial is to evaluate the efficacy of psilocybin administered with Acceptance and Commitment Therapy (ACT) as an intervention to reduce post-traumatic stress disorder (PTSD) symptom burden in adult (aged 18-65) survivors of intimate partner violence (IPV).\n\nThis trail will test the following 2 aims:\n\nAIM 1 : To compare the efficacy of a therapeutic psilocybin dose at improving outcomes on the PCL-5 and CAPS-5 as compared to an active control psilocybin dose in IPV survivors with chronic PTSD.\n\nAIM 2: To evaluate the efficacy of psilocybin on quality of life, cognitive function, motor ability, depression, anxiety, and cognitive flexibility.\n\nParticipants will be asked to:\n\n* Complete a 2 part screening process\n* Attend a baseline assessment\n* Complete a psychoeducation preparation session(s)\n* Attend psilocybin administration session (receive high dose \\[25mg\\] or low dose psilocybin \\[1mg\\])\n* Complete 5-6 weekly sessions of ACT\n* Repeat outcome measures at 1-week, 4 weeks, 3 months (online questionnaires only), and 6 months post-psilocybin administration.",[88,125],[324,325,326],"Psychotherapy","Psilocybin","Acceptance and Commitment Therapy","2026-05-11",{"date":329,"type":36},"2026-05-14",{"date":331,"type":22},"2026-08-01",{"date":333,"type":22},"2029-08-01",{"name":335,"class":43},"University of Calgary",{"id":337,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":338,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":26,"conditions":340,"keywords":341,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":346,"leadSponsor":347,"locationsCount":44},"100623791",{"count":21,"type":22},[25],[28],[30,31],"2026-05-04",{"date":344,"type":36},"2026-05-06",{"date":38,"type":22},{"date":40,"type":22},{"name":42,"class":43},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":23,"phases":358,"briefSummary":359,"conditions":360,"keywords":362,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":44},"100531058","phase-2-examining-intranasal-oxytocin-augmentation-of-brief-couples-therapy-for-veterans-with-ptsd-100531058","NCT06194851","Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD","A Randomized Clinical Trial Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD","CBCT-OT RCT","Inclusion Criteria:\n\nInclusion criteria for Veteran:\n\n1. Be a Veteran (age 18 or older) with a current DSM-5 diagnosis of PTSD (as assessed by the CAPS-5 with a minimum severity score of 25) no less than 3 months after the index trauma occurred (to allow for potential natural recovery)\n2. Be on a stable psychoactive medication regimen for at least 4 weeks (if applicable)\n3. Be enrolled and eligible to receive care at the VASDHS\n\n   Inclusion criteria for Partner:\n4. Be an intimate partner (age 18 or older) who is willing to participate in the intervention (partners can also be Veterans but cannot meet criteria for possible PTSD per the PCL-5)\n\n   Inclusion criteria for Veteran and Partner:\n5. Be married, or cohabitating for at least 6 months\n6. Willing to be randomized into either treatment condition (bCBCT + OT or bCBCT + PL)\n7. Agree to have assessment and treatment sessions audio\u002Fvideo recorded\n8. Agree not to receive other individual trauma-focused psychotherapy for PTSD or any form of conjoint therapy during the treatment portion of the study\n9. Have the capacity to participate in virtual care (access to internet via DSL or a cable provider, private space)\n\n   Exclusion Criteria:\n\n   Exclusion criteria for Veteran and Partner:\n10. Current substance dependence in either member of the couple not in remission for at least 3 months, as assessed by the Alcohol Use Disorders Identification Test (AUDIT)74 and Drug Abuse Screening Test (DAST)75\n11. Any current uncontrolled psychotic disorder in either member of the couple as assessed by positive screen on the Prime Screen-Revised (PS-R). Exclusion to be determined following case consult by PI or other clinician.\n12. Imminent suicidality or homicidality in either member of the couple (e.g., C-SSRS)\n13. Any severe cognitive or medical impairment in either member of the couple making it difficult to regularly attend weekly couples psychotherapy\n14. Any perpetration of severe physical or sexual relationship aggression (as assessed by the CTS-2) or fear\u002Fintimidation (3-item IPV screen, Couples Questionnaire) in the past year\n\n    Exclusion criteria for Veteran:\n15. Severe ongoing medical problems, including heart disease, uncontrolled hypotension (systolic blood pressure \\\u003C100 mm Hg) or hypertension (systolic BP \\>130 or diastolic BP \\> 80 mm Hg), and neuroendocrinological disorders (e.g., diabetes). Exclusion to be determined in collaboration with study physician following completion of physician's one-on-one appointment with Veteran and review of all relevant information (e.g., risk factors, health history, concomitant medications, etc.) from Veteran's VA medical record and study screening\u002Fassessment processes including selfreport measures and blood pressure measurement. Additionally, Veterans for whom the study physician has elevated concern, will be asked to attend an in-person visit at a VA medical center, clinic, or the Veterans Medical Research Foundation before enrollment.\n16. Positive screen (7+) for borderline personality disorder (BPD) as assessed by the MacLean Screening Instrument for BPD76. Exclusion to be determined following case consult by PI or other clinician.\n17. Pregnancy, delivery in the past 6 months, current breastfeeding, or the ability to become pregnant while not practicing an effective method of contraception. If able to become pregnant, Veteran must have a highly sensitive negative urine pregnancy test verified visually via telehealth or in-person at the Veterans Medical Research Foundation by research staff at study entry and prior to each medication administration during treatment. Veteran must verbally confirm that they completed the test themselves that day. Veteran must also agree to use an effective birth control method from study entry until conclusion of treatment to prevent pregnancy. The ability to become pregnant is defined as: assigned female at birth, fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.\n\n    Effective birth control methods include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, oral hormones, a barrier contraception method (e.g., male or female condoms, diaphragm, cap), or vasectomized sole sexual partner.\n\n    Pregnancy tests will be purchased by the study and mailed to Veteran unless PI has approved waiver of testing requirement.\n18. Known allergy to preservatives (i.e., Methylparaben, Propylparaben, Glycerin, Sodium Benzoate, Potassium Sorbate, and Disodium EDTA) utilized in oxytocin nasal spray.",{"count":357,"type":22},240,[174],"Leveraging veterans' intimate relationships during treatment for posttraumatic stress disorder (PTSD) has the potential to concurrently improve PTSD symptoms and relationship quality. Brief Cognitive-Behavioral Conjoint Therapy (bCBCT) is a manualized treatment designed to simultaneously improve PTSD and relationship functioning for couples in which one partner has PTSD. Although efficacious in improving PTSD, the effects of CBCT on relationship satisfaction are small, especially among Veterans. Pharmacological augmentation of bCBCT with intranasal oxytocin, a neurohormone that influences mechanisms of trauma recovery and social behavior, may help improve the efficacy of bCBCT. The purpose of this randomized placebo-controlled trial is to compare the clinical and functional outcomes of bCBCT augmented with intranasal oxytocin (bCBCT + OT) versus bCBCT plus placebo (bCBCT + PL). The investigators will also explore potential mechanisms of action: communication, empathy, and trust.",[361],"Post-Traumatic Stress Disorder (PTSD)",[28,363,364,365,366],"Oxytocin","Relational Problems","Brief Cognitive Behavioral Conjoint Therapy","Veterans","2026-04-27",{"date":342,"type":36},{"date":370,"type":36},"2024-10-28",{"date":372,"type":22},"2028-09-30",{"name":73,"class":74},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":23,"phases":383,"briefSummary":384,"conditions":385,"keywords":386,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":137},"100626055","nurse-led-ptsd-treatment-in-primary-care-100626055","NCT07430657","Nurse-Led PTSD Treatment in Primary Care","A Hybrid Implementation-Effectiveness Trial of Nurse-Delivered Post-Traumatic Stress Disorder Treatment in Primary Care","Inclusion Criteria:\n\n* o PTSD + trauma exposure (PCL-5 score ≥28, plus trauma endorsed on LEC-5\u002FCAPS)\n\n  * Life-threatening CV event in the last 90 days (including myocardial infarction\u002Fheart attack, acute cerebrovascular accident\u002Fstroke, sudden cardiac arrest, acute decompensated heart failure, or life-threatening arrhythmia requiring cardioversion or defibrillation).\n  * Primary care patient at Rush University Medical Center\n\nExclusion Criteria:\n\n* o Safety risk (documented suicidal ideation\u002Fneed for acute psychiatric care)\n\n  * NET conflict (actively receiving psychotherapy\u002FPTSD treatment)\n  * Cognitive\u002Fdecisional non-capacity (University of California, San Diego Brief Assessment of Capacity to Consent \\[UBACC\\] ≤ 14.5)",{"count":382,"type":22},100,[25],"Purpose of the Study Post-traumatic stress disorder (PTSD) is a common and serious condition, but many people cannot get the help they need because there are not enough mental health specialists (like psychologists or psychiatrists) available. This study is testing a new program called NurseNET. The goal of NurseNET is to train nurses to provide a proven, short-term trauma treatment called Narrative Exposure Therapy (NET).\n\nWhy This Study is Important Most people see their nurse or doctor for health concerns. Because nurses are highly trusted and already work on the front lines of healthcare, they may be in the best position to offer PTSD treatment quickly and conveniently. This study aims to see if nurse-led care can bridge the gap between patients and the treatment they deserve.\n\nWhat the Study Involves Researchers will enroll 100 participants who have symptoms of PTSD. Participants will work with a trained nurse in a primary care setting to complete the NurseNET program.\n\nThe Treatment: The program consists of 4 to 6 sessions. During these sessions, the nurse helps the patient talk through their life story and process difficult memories in a safe, supportive way.\n\nWhat We Are Measuring: The research team will look at several factors to see if the program is successful:\n\nEffectiveness: Do PTSD symptoms improve after working with the nurse?\n\nFeasibility and Acceptability: Do patients and nurses find this type of care easy to use and helpful?\n\nHealth Impact: Since PTSD is linked to heart health, the study will also look at whether the treatment improves things like blood pressure or physical activity levels.\n\nGoal of the Research By the end of this study, researchers hope to show that nurses can safely and effectively provide trauma care. If successful, this model could be used across the United States to make PTSD treatment much easier to access for everyone.",[88],[387,388,389],"post traumatic stress disorder","primary care","nurse","2026-04-23",{"date":392,"type":36},"2026-04-29",{"date":394,"type":36},"2026-03-30",{"date":396,"type":22},"2029-09",{"name":398,"class":43},"Rush University Medical Center",{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":195,"enrollmentInfo":406,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":413,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":431,"locationsCount":44},"100633207","non-invasive-vagus-nerve-stimulation-nvns-for-post-traumatic-stress-disorder-ptsd-100633207","NCT07523685","Non-invasive Vagus Nerve Stimulation (nVNS) for Post-Traumatic Stress Disorder (PTSD)","Non-invasive Vagus Nerve Stimulation (nVNS) for Adjunctive Treatment of Symptoms Associated With Post-Traumatic Stress Disorder (PTSD)","Inclusion Criteria:\n\n* PTSD diagnosis as determined by the Structured Clinical Interview for DSM-5 (SCID) interview for PTSD\n* CAPS-5 score \\> or = 35\n* Between the ages of 18 and 70 years\n* Has PTSD symptoms and either is not taking PTSD medications or stable on PTSD medications for 3 months.\n* Agrees to refrain from initiating or changing the type, dosage, or frequency of any prophylactic medications for indications other than PTSD that, in the opinion of the clinician may interfere with the study objectives (e.g., antidepressants, anticonvulsants, beta-adrenergic blockers, etc.)\n* Agrees to use nVNS as instructed and follow all of the requirements of the study including Follow-up Visit requirements\n* Able to provide written informed consent\n* Must have a primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial\n\nExclusion Criteria:\n\n* Psychiatric or cognitive disorder and\u002For behavioral problems that, in the opinion of the clinician, may interfere with the study, such as symptoms of suicidal or homicidal risk.\n* Evidence of a major medical or neurological illness on physical examination or as a result of laboratory studies (CBC, BUN, creatinine, blood sugar, electrolytes, liver and thyroid function tests, urinalysis, and EKG), such as cardiovascular, gastrointestinal, hepatic, renal, neurologic or other systemic illness; which in the opinion of the investigator or industry partner interferes with the study\n* Cervical vagotomy or structural abnormality at the nVNS treatment site (e.g., lymphadenopathy, previous surgery, abnormal anatomy)\n* Pain at the nVNS treatment site (e.g., dysesthesia, neuralgia, cervicalgia)\n* Currently implanted with an electrical and\u002For neurostimulator device (e.g., cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, cochlear implant, sphenopalatine ganglion stimulator, occipital nerve stimulator)\n* Pregnant or thinking of becoming pregnant during the study period, or of childbearing years and unwilling to use an accepted form of birth control\n* Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self-assessments is compromised (e.g., homeless, developmentally disabled, prisoner)\n* Patients with a stellate ganglion block (SGB)\n* An employee of the Investigator or the clinical study site\n* Recent (within 4 weeks) or concurrent use of a rapid-acting antidepressant agent (e.g., ketamine, esketamine, ECT) and\u002For other non-invasive stimulation therapy (e.g., TMS, transcranial focused ultrasound)",{"count":147,"type":22},[25],"The goal of this clinical trial is to evaluate the safety and effectiveness of the gammaCore non-invasive vagus nerve stimulation (nVNS) device as an additional treatment for symptoms of post-traumatic stress disorder (PTSD) in adults.\n\nThe vagus nerve connects the brain with many organs and systems in the body and plays a role in regulating stress and emotional responses. The gammaCore device is a handheld, rechargeable medical device that delivers gentle electrical stimulation to the vagus nerve through the skin on the side of the neck. By stimulating this nerve, the device may help reduce PTSD symptoms.\n\ngammaCore is cleared by the U.S. Food and Drug Administration (FDA) for the treatment and prevention of migraine and cluster headache. It has not yet been approved for the treatment of PTSD. This study is being conducted to better understand whether this type of stimulation may help improve PTSD symptoms and to evaluate its safety when used for this purpose.\n\nThe main questions this study aims to answer are:\n\n* Is non-invasive vagus nerve stimulation safe for people with PTSD when used regularly at home?\n* Does treatment with the gammaCore device improve PTSD symptom severity over time?\n\nIn this study, approximately 40 adults with PTSD will participate in an open-label pilot study.\n\nParticipants will first complete a 4-week baseline period in which their PTSD symptoms are monitored. This allows researchers to understand each participant's symptoms before starting the intervention.\n\nParticipants will then begin a 12-week treatment period using the gammaCore device at home. During this time, participants will apply the device to the side of the neck for short stimulation sessions each day as instructed by the study team.\n\nParticipants will attend six study visits, some conducted remotely and some in person. These visits include screening, training on how to use the device, and follow-up assessments. During the study, participants will complete questionnaires and clinician-administered assessments that measure PTSD symptoms and quality of life. Researchers will also monitor participants for any side effects or medical problems related to the device.\n\nBy collecting information on symptoms, safety, and device use, this study will help researchers understand whether non-invasive vagus nerve stimulation could become a useful treatment option for people living with PTSD.",[91,88,410,411,412,246,200],"PTSD - Post Traumatic Stress Disorder","Post Traumatic Stress Disorder","Post Traumatic Stress Disorders",[91,414,415,416,417,418,419,420,421,422,423,424,425],"nVNS","Non-invasive","vagus nerve stimulation","vagus nerve stimulator","Post-traumatic stress disorder","neuromodulation","non-invasive vagus nerve stimulation (nVNS)","Adjunctive treatment of post traumatic stress disorder","gammaCore","VNS","peripheral nerve stimulation","brain stimulation","2026-04-22",{"date":367,"type":36},{"date":429,"type":36},"2026-03-02",{"date":184,"type":22},{"name":432,"class":433},"Acacia Clinics","INDUSTRY",{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":145,"enrollmentInfo":441,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":444,"conditions":445,"keywords":451,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":44},"100628166","the-step-mied-trial-digital-stepped-care-for-emotional-disorders-100628166","NCT07458100","The STEP-MIED Trial: Digital Stepped-Care for Emotional Disorders","Effectiveness and Cost-effectiveness of a Digital Stepped-care Mindfulness Intervention for Recovery From Emotional Disorders: a Multicentre Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age: 18-65 years.\n2. Diagnosed with an emotional disorder by a outpatient psychiatrist, including depressive disorders, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder), obsessive-compulsive disorder, post-traumatic stress disorder, and eating disorders (e.g., anorexia nervosa, bulimia nervosa).\n3. Symptom severity meeting the threshold: PHQ-9 score ≥10 or GAD-7 score ≥8.\n\nExclusion Criteria:\n\n1. Current diagnosis of psychotic disorders or bipolar disorder.\n2. Current organic mental disorders, pervasive developmental disorders, severe cognitive impairment, or substance use disorders.\n3. Current suicide risk (PHQ-9 item 9 score \\>2).\n4. Antisocial personality disorder.\n5. Severe medical illnesses that may affect intervention participation or require recent hospitalization.\n6. Previous participation in a systematic 8-week mindfulness course.\n7. Inability to access the internet.",{"count":442,"type":22},464,[25],"The goal of this clinical trial is to evaluate the effectiveness and cost-effectiveness of a digital mindfulness-based intervention in adults (aged 18-65) diagnosed with emotional disorders like depression or anxiety. The main questions it aims to answer are:\n\n* Does adding a digital mindfulness intervention to usual care help people recover from emotional disorders faster and more sustainably over two years?\n* Is this combined approach more cost-effective than usual care alone? Researchers will compare the group receiving the digital mindfulness intervention plus their usual treatment to the group receiving only their usual treatment to see if the intervention leads to better long-term recovery and represents good value for money.\n\nParticipants in the intervention group will:\n\n* Attend eight weekly 2-hour online group mindfulness sessions.\n* Use a WeChat mini-program for 49 days of guided mindfulness exercises and daily tasks.\n* Patients who have not achieved reliable recovery after group retraining voluntarily participate in individual UP\\&MIED counseling.\n* Complete regular questionnaires and interviews over two years to track their progress.\n\nAll participants will continue to receive their usual medical care from their doctors throughout the study.",[446,447,448,449,200,450],"Emotional Disorders","Depressive Disorder","Anxiety Disorders","Obsessive-Compulsive Disorder","Eating Disorders",[452,61,453,454,455,446],"Cost-effectiveness","Recovery","randomized controlled trial","stepped-care","2026-04-18",{"date":458,"type":36},"2026-04-21",{"date":460,"type":36},"2026-03-23",{"date":462,"type":22},"2028-05",{"name":464,"class":43},"Peking University",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":240,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":4},"100633182","a-digital-cognitive-intervention-for-intrusive-memories-after-trauma-100633182","NCT07523360","A Digital Cognitive Intervention for Intrusive Memories After Trauma","A Novel Digital Cognitive Intervention Targeting Intrusive Memories Among Trauma-Exposed Individuals: A Randomised Clinical Trial","Inclusion Criteria:\n\n1. Meet DSM-5 Criterion A for PTSD, which stipulates exposure to an event involving serious injury or a threat to one's own or another's physical well-being, either through direct experience or witnessing.\n2. Participants needed to exhibit symptoms from at least three of the five core PTSD symptom domains outlined in DSM-5: intrusive memories (Criterion B), persistent avoidance of trauma-related stimuli (Criterion C), negative alterations in cognitions and mood (Criterion D), alterations in arousal and reactivity (Criterion E), and symptoms lasting for at least one month (Criterion F).\n3. The total score of CAPS-5 ≥ 33.\n4. Have internet access and have access to a personal computer.\n5. Have not taken part in a previous study of this intervention from this research team.\n\nExclusion Criteria:\n\n1. Fewer than 5 intrusive memories during the baseline week (Week 0).\n2. IQ score lower than 80.\n3. A current diagnosis of schizophrenia, obsessive-compulsive disorder (OCD), a severe personality disorder judged to interfere with treatment adherence, or acute suicidal behavior.\n4. Have severe substance dependence.",{"count":473,"type":22},123,[25],"Intrusive traumatic memories frequently trigger severe distress and psychological disorders like PTSD. Traditional therapies require explicit trauma recall, which often causes severe patient distress and leads to treatment avoidance. To address this, our study introduces a novel, less aversive intervention combining unconscious visual processing with bilateral eye movement to mitigate these intrusive memories.\n\nUtilizing a randomized, three-arm design (comparing standardized trauma-related images, patient-provided images, and neutral images, all paired with bilateral eye movements), we plan to recruit participants who have experienced severe trauma and report ≥ 5 intrusive memories weekly, targeting a final sample of 40 patients per arm. The primary outcome is the frequency of intrusive memories. Secondary and additional outcomes include PTSD severity (CAPS-5, PCL-5, IES), depression, anxiety, borderline symptoms, functional improvements, subjective intervention distress, and dropout rates.",[361,477],"Intrusive Memories of Traumatic Event(s)","2026-04-04",{"date":480,"type":36},"2026-04-13",{"date":482,"type":22},"2026-04-10",{"date":484,"type":22},"2028-05-10",{"name":486,"class":43},"Zhu Zijian",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":240,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":496,"briefSummary":497,"conditions":498,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":505,"locationsCount":4},"100631072","tetris-intervention-following-subliminal-reactivation-for-intrusive-memories-100631072","NCT07495917","Tetris Intervention Following Subliminal Reactivation for Intrusive Memories","A Tetris Intervention Following Subliminal Reactivation for Reducing Intrusive Memories in Trauma-exposed Individuals: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Meet DSM-5 PTSD Criterion A (eg, exposure to actual or threatened death). Have experienced one or more traumatic events.\n2. Experienced five or more intrusive memories during the baseline week.\n3. Have internet access and have access to a personal computer.\n4. Be willing to provide consent and able to complete study procedures and be contacted by the study team.\n\nExclusion Criteria:\n\n1. Have fewer than five intrusive memories during the baseline week.\n2. A current diagnosis of schizophrenia, obsessive-compulsive disorder (OCD), a severe personality disorder judged to interfere with treatment adherence, or acute suicidal behavior.\n3. Have severe substance dependence.",{"count":495,"type":22},106,[25],"Post-Traumatic Stress Disorder (PTSD) is characterized by recurrent, intrusive memories of traumatic events that cause significant distress and functional impairment. Although trauma-focused treatments are effective, they typically require deliberate recollection of traumatic experiences, which can be distressing and may contribute to treatment avoidance or dropout.\n\nIn previous experimental studies conducted with healthy participants, we demonstrated that unconscious reactivation of trauma-related cues, followed-after a brief delay corresponding to the memory reconsolidation window-by a visuospatial interference task (Tetris gameplay), reduced the frequency and emotional intensity of intrusive memories. These findings suggest that memory representations may be modifiable during reconsolidation without requiring conscious recall.\n\nBuilding on this work, the present randomized controlled trial (RCT) aims to evaluate the clinical efficacy and tolerability of this reconsolidation-based intervention in trauma-exposed individuals experiencing five or more intrusive memories per week.",[246,477],"2026-03-31",{"date":501,"type":36},"2026-04-06",{"date":482,"type":22},{"date":504,"type":22},"2027-07-30",{"name":506,"class":43},"Shaanxi Normal University",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":17,"minAge":170,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":516,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":137},"100601869","neuromodulation--prolonged-exposure-therapy-evaluation-of-a-technology-enhanced-integrated-treatment-for-pain-and-ptsd-100601869","NCT07116109","Neuromodulation + Prolonged Exposure Therapy: Evaluation of a Technology-Enhanced, Integrated Treatment for Pain and PTSD","Neuromodulation + Prolonged Exposure Therapy: Evaluation of a Technology-Enhanced, Entirely Remote 2-Week Integrated Treatment for Pain and PTSD","Inclusion Criteria:\n\n* Presence of musculoskeletal, chronic, non-cancer pain with a rating of ≥ 3 out of 10 on a 0-10 on the Defense and Veterans Pain Rating Scale (DVPRS) and a pain intensity and interference score of 1 standard deviation above PROMIS normative data (see Measures section below). Symptoms will be required to be of at least six months duration and verified diagnosis in their medical chart authorized by informed consent\n* Diagnosis of PTSD assigned on the basis of the Clinician Administered PTSD Scale (CAPS-5) and PCL-5 ≥ 30\n* willing to participate in study randomization, treatment assignment, and assessments.\n\nExclusion Criteria:\n\n* Having a household member who is already enrolled in the study\n* Active psychosis or dementia at screening\n* Suicidal ideation with clear intent\n* Current substance dependence\n* current opioid medication for pain and\u002For current use of sodium channel blockers, calcium channel blockers, or N-Methyl-D-aspartate receptor antagonists, because these medications can block tDCS effects\n* pregnancy and\u002For lactation\n* concurrent enrollment in another pain clinical trial\n* tDCS or medical related contraindications such as open-injury TBI (penetrating injury), seizure disorder (independently of the type of TBI or condition causing the seizure disorder), pregnancy, implanted metal, claustrophobia\n* having pain that is not chronic, presence of severe and frequent migraines, fibromyalgia, or pain caused by a primary condition such as cancer.",{"count":515,"type":22},146,[25],"The purpose of this study is to examine comparative effectiveness of two home-based telemedicine delivered interventions: transcranial Direct Current Stimulation (tDCS) combined with Massed Prolonged Exposure (Massed-PE) vs. Sham tDCS combined with Massed PE, focusing on pain and PTSD outcomes, to determine the comparative effectiveness of the two interventions on process outcomes of patient satisfaction, treatment attrition, and treatment compliance and to explore changes in blood biomarkers associated with stress and inflammatory processes related to pain and PTSD symptom improvements following treatment.",[519,28],"Chronic Pain",[91,521,522],"transcranial Direct Current Stimulation (tDCS)","Traumatic Brain Injury (TBI)",{"date":524,"type":36},"2026-04-03",{"date":526,"type":36},"2025-07-01",{"date":528,"type":22},"2029-06-30",{"name":530,"class":43},"The University of Texas Health Science Center, Houston",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":145,"enrollmentInfo":538,"targetDuration":4,"studyType":23,"phases":540,"briefSummary":542,"conditions":543,"keywords":547,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":137},"100585550","phase-4-ketamine-for-pain-opioid-use-and-mental-health-in-orthopedic-trauma-patients-100585550","NCT06903819","Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients","Ketamine's Impact on Opioid Use, Pain, and Mental Health in Polytraumatized Orthopedic Patients: A Randomized Controlled Trial (KOPM)","Inclusion Criteria:\n\n* Adults aged 18-65\n* Undergoing acute operative fixation for musculoskeletal trauma\n* Injury Severity Score (ISS) greater than 15\n* Ability to provide informed consent (or consent provided by a legally authorized representative)\n\nExclusion Criteria:\n\n* Age under 18 or over 65\n* Use of ketamine for preoperative or postoperative sedation\n* Known allergy or contraindication to ketamine\n* Prior unsuccessful ketamine therapy for major depressive disorder (MDD) or PTSD\n* Severe psychiatric conditions or psychotic features\n* History of dementia or glaucoma\n* Currently engaged in trauma-focused cognitive behavioral therapy or PTSD psychotherapy started within the past 3 months",{"count":539,"type":22},90,[541],"PHASE4","The goal of this clinical trial is to learn if ketamine, given during surgery, can help improve recovery for adults with serious orthopedic trauma. The study will test whether ketamine reduces pain, lowers the need for opioids, and improves mental health outcomes like depression and post-traumatic stress disorder (PTSD).\n\nThe main questions it aims to answer are:\n\nDoes ketamine reduce pain after surgery compared to standard anesthesia?\n\nDoes ketamine reduce the amount of opioids patients need for pain control?\n\nDoes ketamine improve symptoms of depression and PTSD after orthopedic trauma?\n\nResearchers will compare patients who receive ketamine during surgery with those who receive standard anesthesia without ketamine to see if ketamine helps improve both physical and psychological recovery.\n\nParticipants will:\n\nBe randomly assigned to receive either a single dose of ketamine or standard anesthesia during surgery.\n\nReport their pain using a simple pain scale (Visual Analog Scale, VAS).\n\nComplete short surveys about mood and mental health (PHQ-9 for depression and PCL-5 for PTSD) at several time points after surgery.\n\nAllow the research team to review their electronic medical records to measure opioid prescriptions during recovery.\n\nAttend follow-up visits in clinic or by secure telehealth (e.g., Zoom) at 1-7 days, 2-3 weeks, 6 weeks, 3 months, and 6 months after surgery",[544,545,546,57,246],"Orthopedic Trauma Surgery Patients","Postoperative Pain","Opioid Use",[548,549,545,550,57,91,551,552],"Ketamine","Orthopedic Trauma","Opioid Reduction","Musculoskeletal Injury","Trauma Surgery","2026-03-19",{"date":555,"type":36},"2026-03-24",{"date":557,"type":36},"2025-11-06",{"date":462,"type":22},{"name":560,"class":43},"Texas Tech University Health Sciences Center",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":23,"phases":570,"briefSummary":571,"conditions":572,"keywords":575,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":44},"100627319","emdr-integrative-group-protocol-and-individual-treatment-for-patients-with-cancer-a-pilot-study-100627319","NCT07447089","EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study","Combination of the EMDR Integrative Group Protocol and Individual EMDR Treatment in Patients With Advanced Thyroid Cancer: A Pilot Study","Inclusion Criteria:\n\n* cancer diagnosis\n* PTSD (IES-R \\> 32)\n\nExclusion Criteria:\n\n* receiving specialized trauma therapy\n* receiving current psychiatric pharmacological treatment, unless the dosage has been stable for at least 2 months prior to enrollment","100 Years",{"count":7,"type":22},[25],"The main aim of the present process-outcome study is to evaluate the feasibility and the effects of an EMDR-IGTP-OTS group intervention on a sample of people with cancer, by using a process-outcome study design, with repeated measures.",[573,574,246,60],"Thyroid Neoplasms","Neoplasm",[576,577],"Psychoncology","Cancer",{"date":579,"type":36},"2026-03-04",{"date":581,"type":36},"2025-12-05",{"date":583,"type":22},"2026-12-05",{"name":585,"class":43},"Università Cattolica di Milano",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":594,"enrollmentInfo":595,"targetDuration":4,"studyType":23,"phases":596,"briefSummary":597,"conditions":598,"keywords":599,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":44},"100624308","blended-trauma-focused-cognitive-behavioral-therapy-with-compassion-100624308","NCT07407946","Blended Trauma-Focused Cognitive Behavioral Therapy With Compassion","Blended (mHealth) Trauma-Focused Cognitive Behavioral Therapy With Compassion for Adolescents With Post-Traumatic Stress Disorder: Protocol for a Pilot Randomized Controlled Trial in Northern Sweden","b-TF-CBT-C","Inclusion Criteria:\n\n* Adolescents aged 12-17 years.\n* Meet DSM-5 criteria for post-traumatic stress disorder (PTSD) confirmed by diagnostic interview (MINI-KID).\n* Score ≥25 on the Child and Adolescent Trauma Screen (CATS-2) at baseline.\n* Receiving care within routine child and adolescent psychiatric services in participating regions.\n* Have a non-offending caregiver willing and able to participate in caregiver components of treatment.\n* Able to communicate in Swedish sufficiently to engage in treatment and assessments.\n* Provide informed assent\u002Fconsent, with caregiver consent according to age and regulations.\n\nExclusion Criteria:\n\n* Acute suicidality or risk requiring inpatient care.\n* Active psychotic disorder or severe dissociative symptoms that interfere with participation.\n* Autism spectrum disorder, severe eating disorder, or obsessive-compulsive disorder requiring primary specialized treatment.\n* Ongoing trauma exposure or unstable living conditions that would prevent safe participation.\n* Cognitive impairment or medical condition that precludes participation in psychotherapy or digital components.\n* Substance use disorder requiring treatment, or regular use of benzodiazepines (\\> once per week).\n* Concurrent trauma-focused psychotherapy or recent initiation\u002Fdiscontinuation of psychotropic medication (within the past 6 weeks), or planned medication changes during the study period.","17 Years",{"count":147,"type":22},[25],"Brief Summary\n\nThe goal of this clinical trial is to evaluate the feasibility and acceptability of a blended (mHealth) Trauma-Focused Cognitive Behavioral Therapy with Compassion (bTF-CBT-C) for adolescents with post-traumatic stress disorder (PTSD) in routine child and adolescent psychiatric services in northern Sweden. The main questions it aims to answer are:\n\n* Is bTF-CBT-C feasible to deliver in routine care, as indicated by recruitment, retention, adherence to sessions and app modules, data completeness, and adverse events?\n* Is bTF-CBT-C acceptable to adolescents, caregivers, and therapists, as indicated by satisfaction, therapeutic alliance, digital treatment evaluation, and qualitative interviews? Researchers will compare bTF-CBT-C to standard TF-CBT to explore whether the blended format shows similar or potentially improved patterns in clinical outcomes (e.g., PTSD symptoms, emotion regulation, and self-compassion) and to estimate variability needed to plan a future non-inferiority trial.\n\nParticipants will:\n\n* Complete eligibility screening and baseline assessments, including a diagnostic interview for PTSD.\n* Be randomized to either bTF-CBT-C or standard TF-CBT.\n* Receive trauma-focused treatment over time, with caregiver involvement in both groups.\n* In the bTF-CBT-C group, use a secure mobile app for stabilization modules and exercises, together with therapist-led video sessions and selected in-person meetings.\n* Complete assessments at baseline, after stabilization, post-treatment, and at 6-month follow-up, and provide feedback about their experiences (questionnaires and interviews).",[246],[600,601,602,603,604,605,606,607,608,609,610,611,612,613,614],"post-traumatic stress disorder (ptsd)","Adolescent","Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)","Blended psychotherapy","Digital mental health","mHealth intervention","Compassion-focused therapy","Self-compassion","Emotion regulation","Shame and self-criticism","Caregiver involvement","Child and adolescent psychiatry","Rural mental health","Telehealth","Pilot randomized controlled trial","2026-02-24",{"date":617,"type":36},"2026-02-27",{"date":619,"type":36},"2026-02-23",{"date":621,"type":22},"2029-12-31",{"name":623,"class":43},"Umeå University",{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":628,"acronym":629,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":17,"minAge":631,"maxAge":51,"enrollmentInfo":632,"targetDuration":4,"studyType":23,"phases":634,"briefSummary":636,"conditions":637,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":646,"locationsCount":44},"100625124","phase-3-sleep-disturbances-in-children-and-adolescents-with-post-traumatic-stress-disorder-ptsd-a-randomized-double-blind-placebo-controlled-trial-to-investigate-the-efficacy-of-pediatric-prolonged-release-melatonin-100625124","NCT07418554","Sleep Disturbances in Children and Adolescents With Post-traumatic Stress Disorder (PTSD): a Randomized Double-blind Placebo-controlled Trial to Investigate the Efficacy of Pediatric Prolonged-release Melatonin","MelatoSomKids","Inclusion Criteria:\n\nChildren and adolescents (2 -17.5 years) with:\n\n* A diagnosis of post-traumatic stress disorder (PTSD) as defined by DSM-5 (American Psychiatric Association, 2013)\n* Current significant sleep disturbances defined as ≤6 hours of continuous sleep and\u002For ≥0.5-hour sleep latency from lights-off on 3 out of 5 nights and\u002For nightmare disorder as defined by the International Classification of Sleep Disorders, Third Edition (ICSD-3, Sateia, 2014), for a minimum 3 months, based on parent report and patient medical history\n* No response to at least 4 weeks of sleep hygiene\n* Negative pregnancy test for females with childbearing potential\n* Written informed consent provided by both parents or a legal guardian, as well as the children \u002F adolescents themselves, if possible\n* Stable doses of non-excluded medications for at least 3 months\n\nExclusion Criteria:\n\n* Known systemic or severe acute disease whose care would hinder attendance at appointments\n* Pregnancy, breastfeeding\n* Known diagnosis of another significant sleep disorder (e.g., moderate to severe sleep apnea)\n* Treatment with any form of melatonin within 2 weeks prior to screening\n* Unresponsiveness to previous prolonged release melatonin within the 2 years prior to the study\n* Known allergy to melatonin or lactose\n* Use of prohibited medication (benzodiazepine, z-drug, antihistaminic, among others) within 2 weeks prior to screening\n* Start of a cognitive behavioural therapy (CBT) targeting sleep disturbances or mood disorders, within 6 weeks before study inclusion\n* Participation in a clinical trial within the last month prior to the study\n* Transmeridian travel (\\> 2 time zones) within the month before the start of the study\n* Females not using contraceptives who are sexually active, pregnant, and\u002For breastfeeding\n* Other reasons: inability to receive clear information, inability to participate in the entire study, lack of coverage by the social security system, refusal to sign consent.","2 Years",{"count":633,"type":22},120,[635],"PHASE3","Among the most sensitive and persistent symptoms of post-traumatic stress disorder (PTSD) in children are sleep disturbances in the insomnia spectrum (sleep onset disturbances, fragmented sleep with multiple nocturnal awakening, early morning awakening) as well as nightmares, affecting over 50% of children and adolescents one year after the initial trauma. There are currently no gold standard treatments or pharmacological treatment recommendations specifically for these sleep disturbances in children and adolescents with PTSD, despite the fact that they have a significant effect on daytime functioning and overall mental health of the children and their families. If not treated appropriately, these sleep disturbances in children and adolescents persist over time, and further increase anxiety in children. Sleep disturbances associated with PTSD are predictive of the persistence and long-term outcome of PTSD itself and associated depressive symptomatology, and of a decreased response rate to cognitive-behavioral psychotherapy for PTSD.\n\nWe have previously shown in an international multicenter study that pediatric prolonged release melatonin (PedPRM) has high beneficial effects on sleep disturbances of the insomnia spectrum in children ages 2-17.5 years with autism spectrum disorder, and consecutive positive effects on children's daytime behavior, including anxiety and depressive symptomatology. Its benefit-risk ratio has proven to be excellent over a 2-year follow-up. Beyond its therapeutic benefit on mental health through improvement of sleep, melatonin may have a direct effect on reducing anxiety levels and overall daytime functioning in children, as well as sleep and daytime function in caregivers.\n\nOur study will be the first randomized controlled trial investigating the efficacy of prolonged release melatonin on sleep disturbances in children and adolescents with PTSD, as well as on PTSD symptoms, associated daytime function and overall mental health in these children and their caregivers.",[246,638],"Current Significant Sleep Disturbances","2026-02-10",{"date":641,"type":36},"2026-02-18",{"date":643,"type":22},"2027-01-01",{"date":645,"type":22},"2029-06-01",{"name":647,"class":43},"University Hospital, Strasbourg, France",{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":652,"acronym":653,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":145,"enrollmentInfo":655,"targetDuration":4,"studyType":23,"phases":656,"briefSummary":657,"conditions":658,"keywords":659,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":663,"lastUpdatePostDateStruct":664,"startDateStruct":666,"completionDateStruct":668,"leadSponsor":670,"locationsCount":44},"100611827","targeted-accelerated-tms-for-post-traumatic-stress-disorder-100611827","NCT07245641","Targeted Accelerated TMS for Post-Traumatic Stress Disorder","TAP","Inclusion Criteria\n\n* Age 18-65\n* DSM-5 diagnosis of PTSD per PTSD Checklist for DSM-5 (CAPS-5)\n* At least moderate symptoms of PTSD per PCL-5 (≥21)\n* English proficiency sufficient to understand risks\u002Fbenefits\n* No new medications or medication increases before, during, or after aTMS\n* Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial\n* Agreement to lifestyle considerations:\n* Abstain from becoming pregnant from screening to one-month after treatment (the MRI visit)\n* Continue usual intake patterns of caffeine- or xanthine-containing products (e.g. coffee, tea, soft drinks, chocolate) throughout treatment\n* No changes to routine intake of alcohol, tobacco, and recreational drugs if patients are using them at baseline for at least 24 hours before the start of each MRI and TMS session",{"count":147,"type":22},[25],"Post-traumatic stress disorder (PTSD) is a highly prevalent and debilitating condition among veterans and active-duty military personnel, with rates as high as 30% in certain combat-exposed populations. Conventional treatments such as prolonged exposure therapy and pharmacotherapy have limited efficacy and high dropout rates, highlighting the need for novel, rapidly effective interventions.\n\nTranscranial magnetic stimulation (TMS) has been well established for treatment-resistant depression (TRD). Traditional TMS, which involves 6 to 7 weeks of daily, weekday scalp-targeted treatment, shows open-label response and remission rates of 58.1% and 30%, respectively. However, such protocols may be impractical for military personnel with limited medical leave. A new form of accelerated TMS (aTMS) that involves 10 imaging-guided treatments per day for 5 consecutive days has demonstrated substantial antidepressant benefits within days and response rates of 69% at 1-month follow-up. This protocol has not been tested for PTSD, in part because there was no causally informed brain circuit target. In this study, the investigators will test aTMS for PTSD using a novel PTSD circuit that the investigators have derived.",[28],[660,661,91,98,662],"Accelerated Transcranial Magnetic Stimulation","Post traumatic stress disorder","Neuromodulation","2026-01-29",{"date":665,"type":36},"2026-02-02",{"date":667,"type":36},"2025-12-15",{"date":669,"type":22},"2028-01",{"name":671,"class":43},"Brigham and Women's Hospital"]